Adaptive Biotechnologies Corporation - Common Stock (ADPT)
15.35
+0.20 (1.32%)
NASDAQ· Last Trade: Jun 1st, 2:36 PM EDT
Detailed Quote
Previous Close
15.15
Open
14.99
Bid
15.34
Ask
15.35
Day's Range
14.74 - 15.47
52 Week Range
9.320 - 20.76
Volume
870,745
Market Cap
2.22B
PE Ratio (TTM)
-38.38
EPS (TTM)
-0.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,828,447
Chart
About Adaptive Biotechnologies Corporation - Common Stock (ADPT)
Adaptive Biotechnologies is a biotechnology company that focuses on harnessing the power of the immune system for disease detection and treatment. The company specializes in developing advanced diagnostic tests that analyze the DNA and RNA of immune cells to identify specific immune responses related to various diseases, including cancer and autoimmune disorders. By leveraging large-scale sequencing technology and sophisticated bioinformatics, Adaptive aims to provide physicians with critical insights that can help guide personalized treatment options and improve patient outcomes. Through its innovative platform, the company seeks to transform how diseases are diagnosed and treated, making significant contributions to the field of precision medicine. Read More
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026.
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that blew past Wall Street expectations. The report highlighted a dramatic acceleration in the adoption of its clonoSEQ diagnostic test, positioning the company as a
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp wave of year-end tax-loss harvesting has sent many mid-cap and commercial-stage biotech firms into a tailspin. Investors, eager
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
